DS
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers | Molecular systems biology | 2025 | 61 | 23 | |||
| Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder | Molecular therapy. Nucleic acids | 2025 | 29 | 10 | |||
| Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties | Heliyon | 2024 | 286 | 82 | |||
| Zinc for GNAO1 encephalopathy : preclinical profiling and a clinical case | Med | 2024 | 125 | 140 | |||
| Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery | Neural Regeneration Research | 2023 | 99 | 118 | |||
| Cells of the tumor microenvironment speak the Wnt language | Trends in molecular medicine | 2023 | 126 | 4 | |||
| Chlorin endogenous to the north pacific brittle star ophiura sarsii for photodynamic therapy applications in breast cancer and glioblastoma models | Biomedicines | 2022 | 498 | 161 | |||
| Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation | Acta neuropathologica communications | 2022 | 271 | 138 | |||
| Marine natural products from the russian pacific as sources of drugs for neurodegenerative diseases | Marine drugs | 2022 | 159 | 142 | |||
| Pediatric encephalopathy: cinical, biochemical and cellular insights into the role of Gln52 of GNAO1 and GNAI1 for the dominant disease | Cells | 2021 | 401 | 179 |
